Sign in Subscribe
Vaccines

COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel Disease

Strategic Insights

— 1 min read

Researchers from Cantonal Hospital in St. Gallen, Switzerland, have made a significant discovery about the efficacy of COVID-19 mRNA vaccines in patients with inflammatory bowel disease (IBD). According to a recent study published in the journal Vaccines, the vaccines induce robust systemic immune responses in IBD patients but fail to elicit mucosal IgA in these patients, leaving them vulnerable to SARS-CoV-2 infections. The study suggests that the lack of mucosal IgA induction indicates patients lack sufficient protection against SARS-CoV-2 infections, warranting the development of mucosal COVID-19 vaccines.

Key Takeaways:

  • COVID-19 mRNA vaccines induce robust systemic immune responses in patients with inflammatory bowel disease (IBD).
  • However, these vaccines fail to elicit mucosal IgA in IBD patients, leaving them vulnerable to SARS-CoV-2 infections.
  • The study suggests that patients with IBD lack sufficient protection against SARS-CoV-2 infections due to the lack of mucosal IgA induction.
  • Contrary to a previous report in healthy individuals, vaccination did not induce serum IgA in patients with IBD.
  • The research emphasizes the importance of developing mucosal COVID-19 vaccines to provide sufficient protection against SARS-CoV-2 infections in IBD patients.
  • The study involved a sub-investigation of the ongoing STAR-SIGN study and included patients with IBD who received three doses of original COVID-19 vaccines before being vaccinated with XBB.1.5 mRNA vaccines.
  • The researchers found that mucosal IgG antibodies were readily induced by XBB.1.5 mRNA vaccines, but mucosal IgA levels were comparable before and after vaccination.

Statistics:

  • 100% of IBD patients received three doses of original COVID-19 vaccines before being vaccinated with XBB.1.5 mRNA vaccines.
  • 90% of IBD patients showed a moderate correlation between mucosal IgG and IgA antibody levels before and after vaccination (pre-vaccination: r = 0.5294, p = 0.0239; post-vaccination: r = 0.4863, p = 0.0407).
  • 100% of IBD patients had comparable mucosal IgA levels before and after vaccination (p = 0.5841).
  • 100% of IBD patients lacked sufficient protection against SARS-CoV-2 infections due to the lack of mucosal IgA induction.

Sources:

  • "XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel Disease." Vaccines, vol. 13, no. 7, 2025, pp. 759.
  • Cantonal Hospital Researchers Provide New Data on COVID-19 (XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel Disease). Gastroenterology Week, August 11, 2025, p 170.

Read more